title: Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis.
abstract: OBJECTIVE
  To describe the ophthalmologic outcomes of cases of congenital toxoplasmosis treated prenatally and postnatally.
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  Follow-up ophthalmologic examinations of 18 children born to mothers who were infected before 25 weeks gestation were performed concurrently by two ophthalmologists. The infection in these children was first suspected when their mothers seroconverted during gestation. Toxoplasmic infection of the fetus was diagnosed by fetal blood or amniotic fluid analysis. Mothers were treated by a regimen of alternating pyrimethamine-sulfonamides and spiramycin during gestation. Pyrimethamine-sulfonamides treatment was continued from birth to 1 year of age.
  
  
  RESULTS
  The median age of the children was 4.5 years (range 1-11), when the follow-up ophthalmologic examinations were performed. Visual acuity was decreased in only one child, who had extensive bilateral macular and peripheral lesions. A posterior pole scar was noted in four eyes (four children) for whom visual acuity remained normal. Peripheral lesions were observed in nine eyes (five children). Both eyes were normal in 11 of 18 (61%) of the children.
  
  
  CONCLUSIONS
  In these children at a high risk for congenital toxoplasmic retinochoroiditis, a favorable visual outcome was observed in all but one case.
authors.affiliation: Service d'ophtalmologie (A.P.B), Hôpital Cochin, Paris, France. antoine.brezin@cch.ap-hoparis.fr
authors.forename: Antoine P
authors.initials: AP
authors.lastname: Brézin
authors.forename: Philippe
authors.initials: P
authors.lastname: Thulliez
authors.forename: Jacques
authors.initials: J
authors.lastname: Couvreur
authors.forename: Roberto
authors.initials: R
authors.lastname: Nobré
authors.forename: Rima
authors.initials: R
authors.lastname: Mcleod
authors.forename: Marilyn B
authors.initials: MB
authors.lastname: Mets
mesh_terms: D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002825:Chorioretinitis / Q000175:diagnosis*; D004359:Drug Therapy, Combination; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy* / Q000453:epidemiology; D011295:Prenatal Care; D011739:Pyrimethamine / Q000627:therapeutic use; D015572:Spiramycin / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy* / Q000453:epidemiology; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis*; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000981:Antiprotozoal Agents; D015572:Spiramycin; D011739:Pyrimethamine